Infinity Bio logo

Infinity Bio Funding & Investors

Baltimore, MD

Infinity Bio is a Circulating Antibody Repertoire Profiling service company, leveraging a novel technology, MIPSA (Molecular Indexing of Proteins (or Peptides) by Self Assembly) developed by Dr. H. Ben Larman, a pioneer in this field. Our various antigen libraries provide cost effective, comprehensive and quantitative analyses of antibody responses to infections, vaccinations, self-antigens and allergens. Our proprietary method allows for the rapid and flexible content customization. Infinity Bio can design and create customer specific peptide libraries against any target of choice.

infinitybio.com

Total Amount Raised: $4,516,093

Infinity Bio Funding Rounds

  • Seed

    $4,516,093

Funding info provided by Diffbot.